In March 2026, the U.S. Food and Drug Administration (FDA) sent a stern warning letter to Danish pharmaceutical giant Novo Nordisk, alleging serious lapses in how it tracked and reported adverse events tied to its blockbuster GLP‑1 drugs Ozempic and Wegovy. The agency said the company failed to report several serious side effects and even deaths — including a suicide and a disabling stroke — within the required timeframe.

These warnings are drawing heightened scrutiny amid skyrocketing use of GLP‑1 medications for both diabetes and weight loss, sparking fresh debate about drug safety surveillance and transparency. Here’s what you need to know.

What the FDA Found

According to the federal warning letter, which resulted from an FDA inspection of Novo Nordisk’s U.S. headquarters in Plainsboro, New Jersey:

• Inspectors found “serious violations” of post‑marketing adverse drug experience (PADE) reporting rules.
• The company did not submit reports to the FDA within 15 calendar days of learning about certain serious adverse events, as required by law.
• At least three deaths, including one suicide, were not reported within the required window — and in some cases not reported at all.
• A patient who experienced a disabling stroke while on a GLP‑1 drug was not reported because internal processes dismissed the case as “unrelated” to treatment — a determination the FDA ruled was incorrect under reporting rules.

Importantly, the FDA has not asserted that these drugs caused the events. The agency’s concern lies in Novo Nordisk’s failure to follow required reporting procedures.

In its warning letter, the agency emphasized the critical role of accurate, timely adverse event reporting in its mission “to protect and promote public health.” It noted that gaps in reporting could limit the FDA’s ability to detect safety signals and advise patients and clinicians effectively.

Novo Nordisk’s Response

Novo Nordisk acknowledged the warning letter and said it is actively working to address the FDA’s concerns. Anna Windle, Head of Clinical Development, Medical and Regulatory Affairs at Novo Nordisk U.S., stated that the company “takes PADE reporting requirements seriously” and is engaged in ongoing corrective efforts.

The company noted that its progress updates to the agency include expanded safety procedures and remedial actions designed to ensure compliance. Novo has also stressed that the FDA’s letter “does not make any conclusions about the quality or safety of our medicines.”

Why This Matters

GLP‑1 receptor agonists — the class of drugs that includes semaglutide, the active ingredient in Ozempic and Wegovy — have become among the most prescribed medications in the U.S., both for diabetes and off‑label weight loss. Their popularity has skyrocketed in recent years, with millions of prescriptions filled annually.

Because these drugs are used by so many people, robust safety monitoring is essential. Adverse drug experience reporting helps regulators spot rare or unexpected effects that might not emerge in clinical trials alone.

Some experts say that the types of events the FDA cites — stroke and suicidal ideation — are precisely the kinds of serious outcomes regulators need to review in detail to understand whether there’s a pattern worth investigating.

Although the FDA has indicated in recent communications that current evidence does not show a causal link between GLP‑1 drugs and suicidal thoughts or actions, it continues to evaluate reports and advise vigilance.

Expert and Regulatory Takeaways

Safety advocates and clinicians note two broader points:

1. Reporting systems rely on drug makers

Post‑marketing surveillance depends heavily on pharmaceutical companies submitting serious adverse events promptly and completely. Delays or gaps — even if unintentional — can slow regulators’ ability to detect new safety patterns or update prescribing information.

2. Patients and clinicians should communicate

Regardless of regulatory compliance issues, both patients and health care providers are encouraged to report suspected side effects through systems like the FDA Adverse Event Reporting System (FAERS). Prompt reporting helps build a fuller picture of a drug’s safety profile in real‑world use.

Looking Ahead

The warning letter is part of an ongoing review by the FDA and marks a rare public reprimand of a major pharmaceutical manufacturer over safety reporting. While it does not trigger a recall or imply that Ozempic or Wegovy are unsafe, it underscores the importance of transparency and responsiveness in drug safety monitoring as these widely used medications remain central to diabetes and weight management strategies.

As Novo Nordisk works to address the regulatory concerns, patients taking these drugs should continue their prescribed therapies unless advised otherwise by their health care providers — and stay informed about any official updates to warnings or prescribinginformation.